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Introduction: cultivation, medication, activism and 
cannabis policy 
 
Cultivating cannabis in a cold climate 
 
On Friday 23rd February 2018 the medical cannabis bill introduced by UK Member of 
Parliament Paul Flynn1 went in for its second reading in the House of Commons.2 To 
the disappointment of several hundred activists assembled on the patch of green on 
Parliament Square in the freezing cold it never got to a vote, as the discussion on the 
preceding motion, Overseas Electors, dragged on.  
 
The event captured many of the issues transforming the field of drug policy, at least 
as related to cannabis. A large number of demonstrators were middle aged, a few 
had rolled up in wheel chairs, and the police were keeping a respectful distance. 
Cannabis use in the UK, as in many other countries, has come of age, its 
respectability confirmed by the rising flow of scientific evidence of its therapeutic 
benefits. Politics, however, is out of step with scientific advances and changing social 
mores, held back by the counter weight of vested interests, the arrogance of political 
elites, and sheer inertia. Cannabis, whether for medical or non-medical use, remains 
illegal in the UK3, and most other countries, even as a growing number of 
jurisdictions change policy. 
 
That very same week much media attention was given to the case of Alfie, a six year 
old boy from Kenilworth, England, suffering from epilepsy, who responded well to 
cannabis treatment. But in order to obtain medical quality cannabis legally, the family 
had had to move to the Netherlands. Now back in the UK, they are petitioning the 
Home Office to “grant him a licence to use cannabis oil to help soothe his symptoms” 
(Press Association, 2018). The  government is considering the issue at the time of 
writing, and one of the mooted options is to include Alfie in a medical trial.  
 
Unravelling the international system of controls that have been erected over the last 
fifty odd years is a daunting task, and perhaps the main reason why few 
governments have made any effort to correct what the UNODC reported in 2006 as 
an anomaly that is threatening to undermine the credibility of the international control 
system (UNODC, 2006: 186). There certainly was no appetite for change at 
Westminster, where the session ran out of time without the bill being heard.  
 
Since policy makers are reluctant to lead on this issue, change has to come from 
below, driven by local and regional initiatives and a network of activists, growers and 
patients who are transforming the policy landscape. In the US eight states have now 
regulated cannabis production and sale for recreational and medical purposes, and a 
further 21 states have legal provision for medical cannabis only (Snapp and Herrera, 
2018). Canada is planning to establish a similar model at national level this year. 
Uruguay’s mixed approach – home-growing, state-provision of cannabis for purchase 
                                                        
1 Legalisation of Cannabis (Medicinal Purposes) Bill 2017-19   
2
 Ten Minute Rule Bills are a type of Private Members' Bill that are introduced in the House of Commons 
under Standing Order No 23. The ten minute rule allows a backbench MP to make his or her case for a new 
Bill in a speech lasting up to ten minutes. An opposing speech may also be made before the House decides 
whether or not the Bill should be introduced. If the MP is successful the Bill is taken to have had its first 
reading. 
3 
Some cannabis-derived medications are available for a limited number of conditions, as discussed below. 
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through pharmacies, and Cannabis Social Clubs (CSCs) – is ground breaking as the 
first country (and a signatory of the UN conventions) to move towards a state-
monitored regulated market (Hudak et al, 2018). Change is happening around the 
world – cannabis users and activists in other countries (including the UK) want to 
know ‘Why not here?’ 
 
In Europe, quasi-legal retail markets have been in place for decades, such as the 
Dutch Coffeeshop system (Korf, 2008) and ‘pusher street’ in Cristiania, Copenhagen 
(Asmussen Frank, 2008). In many countries, such as Portugal, the Czech Republic 
and Germany, the possession of small quantities has been decriminalised (See 
Release, 2016 for decriminalisation policies across the globe). Even in the UK, a 
number of police forces give low priority to cannabis offences, to the chagrin of drug 
control advocates. Some UK Police and Crime Commissioners go even further, as 
Arfon Jones in North Wales, and Ron Hogg in Country Durham, have deprioritised 
pursuing cannabis consumers and small scale growers. Hogg has met with members 
of UKCSC chapters (Gayle, 2015), and more recently Jones has daringly expressed 
a desire to see cannabis regulated in a similar vein to alcohol (Brennan, 2018). 
 
This street level pragmatism, of effective decriminalisation in some UK regions, has 
had significant social benefits. It has spared tens of thousands of people from being 
branded with a criminal record, as well as saving extensive criminal justice 
resources, yet it has only kicked the can down the proverbial road – or in this case, 
up the supply chain. In the Netherlands, it is known as the “back door problem”. 
Cannabis, sold freely over the counters of hundreds of coffeeshops, is produced and 
delivered to the back door by organised crime groups (Boister, 2016).4 In the past, 
attempts by lawmakers to regulate cannabis supply have foundered on the 
uncompromising stipulations of the international drug control conventions and the 
opposition of EU partners in pursuit of ‘harmonised’ drug policies (Blickman, 2018; 
Boekhout van Solinge, 2017). 
 
In fact, across Europe, drug policy has come to an impasse. Years of investment in 
the provision of harm reduction and treatment have been met with laudable success. 
The transmission rates of infectious diseases are d wn, with regional outbreaks, the 
rate of overdose deaths has stabilised and a large number of problem users are in 
contact with drug services (EMCDDA, 2018). 
 
At the United Nations General Assembly Special Session on Drugs in 2016 
(UNGASS), EU member states spoke with one voice in favour of humane, public-
health focused interventions, in full compliance with human rights. But tolerance and 
a ‘human centred approach’ do not mean legalisation, and nowhere has a ruling 
party committed to the regulation of cannabis markets (Chatwin, 2018).  
 
It is therefore left to civil society, with the support of lower level governance agencies, 
to experiment with different approaches. As well as campaigning for legalisation – 
whether for medical cannabis or for drug use more widely – users and sympathisers 
often engage in the illegal activities of cultivation and supply as well as possession 
and use. It is this activism, and the wider backdrop of cannabis policy change, that 
provides the focus of this special issue. 
 
One model is CSCs, originally developed in Spain to provide members with a reliable 
supply, the opportunity for social use, and a modicum of protection from prosecution 
by pooling resources and sharing responsibility (Arana and Montañés Sánchez, 
                                                        
4 A process that Francisco Thoumi, currently a member of the INCB, has called the cannabis’ “immaculate 
conception” (Blickman, 2018). 
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2011). Well established in parts of Spain, particularly the Basque country, Catalonia 
and Valencia, the model has since been transplanted to countries with a less benign 
legal environment, like Belgium (See the articles by Pardal; Ditchfield; Bone and de 
Hoedt but also Decorte, 2015).  
 
A response, ironically, to changes in legislation in Holland that made it more difficult 
for Belgian visitors to purchase cannabis in coffeeshops close to the border, the 
growth of Belgian CSCs is perhaps one unexpected consequence of supply side 
intervention – a balloon effect.5 As Pardal explains in her contribution (see also 
Pardal 2016), the organisations remain small and operate in a hostile legal 
environment with an uncertain future.  What they have demonstrated, however, is 
how dynamic the demand is for quality cannabis products and non-criminal supply 
sources.  
 
Being able to source and distribute cannabis without making contact with the criminal 
market is also the major motivation for growers in New Zealand and Israel. The 
paper by Wilkins and Sznitman confirms previous work that firmly establishes 
domestic cultivation and ‘social supply’ as the dominant model. The chief motives of 
these growers – committing crimes of drug production and supply – are providing 
family and friends with quality product rather than to make profit.  
 
The ambivalent situation of cannabis, now legal in Uruguay, parts of the US, and 
soon, Canada, widely consumed all over the world, but still controlled under the 
international conventions throws up a dilemma for a country like Jamaica. Here 
cannabis is deeply embedded in social and cultural history, a sacrament in the 
Rastafari religion, and a potent symbol in the anti-colonial struggle and rejection of 
Babylon and all things western (Bone, 2014).  
 
Reform has been long in coming, with well-crafted proposals, such as the 2000 
report of the Ganja Commission, being thrown off course by hostile response from 
the US ambassador. At the time, US governments were pursuing an aggressive drug 
control policy in the Caribbean (Klein, 2004).  
 
But changes in legislation at state level have allowed US companies to develop 
products, assume economies of scale, and position themselves as industry leaders, 
while competitors in other countries are held in check by controls that the US 
government enforces.6 Only with a change in the US approach to regional drugs 
policy under the less interventionist Obama presidency did the Jamaican government 
get some space for policy experimentation. In this issue Machel et al 
discuss the reforms that are preparing the way to what the authors call the Caribbean 
Cannabis economy. But the mooted shift towards a commercial cannabis market is 
fraught with anxiety over the displacement that the influx of foreign capital would 
effect, and frustrations over the slow pace of work of the Cannabis Licensing Agency. 
 
In Jamaica, at least, cannabis cultivators have found a voice and are getting 
organised. In most parts of the world the call for change comes from consumers, who 
lobby political representatives, organise marches and run other forms of civil 
protests. There is an activism at work here, a use of symbols and the mobilisation of 
                                                        
5 Though, as noted by Decorte (2015) the emergence of CSCs in Belgian coincided with a relaxation of their 
cannabis laws. In 2005 a joint guideline issued by the College of Public Prosecutors and the Minister of 
Justice called for the lowest prosecution priority to be given to cannabis possession by adults for quantities 
which did not exceed three grams or one cultivated female cannabis plant. 
6
 The International Narcotics Control Strategy Report (INCSR) is delivered annually by the Department 
of State to Congress. It describes the efforts of key countries to attack all aspects of the international 
drug trade and may lead to sanctions on countries that are seen as not fulfilling their obligations. 
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supporters around a specific issue, that both Guerra and Pardal for Mexico and 
Belgium respectively describe as social movements. Guerra’s definition, of 
participants coordinating public representations of “worthiness, unity, numbers, and 
commitments” applies equally to the protesters at Westminster.   
 
Of course, many of the consumers driving change in cannabis policy confound 
societal perceptions and fears of the ‘drug taker’.7 They use cannabis not from 
addiction, the search for pleasure or oblivion but in order to control pain, fight nausea 
or keep any of a number of medical conditions in check. Cannabis, is a drug, in the 
historical sense of the word, in that it has medicinal properties and can be 
therapeutic or noxious depending on dosage. In the 19th century the term ‘drugs’ 
referred to remedies concocted by apothecaries and prescribed by physicians 
(Porter, 1996).8 With the advances in organic chemistry in the late 19th and the early 
20th century cannabis, like many other natural substances, was pushed aside by 
pharmaceutical medications. Over the last thirty years, however, it has been making 
a comeback, and lawmakers are reluctantly aligning legislation with changing 
medical perceptions. 
 
So far, only a handful of European countries have been developing systems for the 
production and prescription of cannabis flowers: The Netherlands (2003), the Czech 
Republic (2013), Italy, Croatia (both 2015), Germany and Poland (both 2017). But 
the journey from repression towards a regulatory system is fraught with difficulties, as 
shown by Grotenhermen in his account of German cannabis legislation. The 
process for patient and medical practitioner is cumbersome, and health insurance 




Most countries still have a long way to travel before even engaging with this level of 
problem. The UK government has been skirting the issue, by allowing one producer, 
GW Pharmaceuticals, to market Sativex (an oromucosal spray) that can be 
prescribed for treating MS-related spasticity where patients do not respond to other 
treatments. Yet, the cost and limited application of Sativex places the medicine 
effectively out of reach of most patients who continue to rely largely on the criminal 
market. As Ditchfield and Godfrey detail in their accounts, this is often a painful 
experience, involving hard encounters with the criminal justice system and constant 
uncertainty over the reliability and quality of the medicine.  
 
Many medical users have therefore started growing for peace of mind and an easier 
life. In some cases, it was simple desperation, as Bone and de Hoet lay out in the 
personal narrative of one patient with a serious case of Crohn’s disease. This is the 
story of a long journey into cultivation and activism inspired by international 
regulatory models and US activists in particular. Several US states, including 
Colorado and California, have upended the legal situation and emerged as world 
leaders in the development of cannabis based products. In other instances, the 
emphasis has been on helping others (Ditchfield), but all growers and users 
                                                        
7 For an in depth look into the prejudices and fears surrounding people who use 
drugs see: The Global Commission on Drugs, 2017 
<http://www.globalcommissionondrugs.org/wp-
content/uploads/2018/01/GCDP-Report-2017_Perceptions-ENGLISH.pdf> 
8 It has even been suggested that Queen Victoria used cannabis medically (Mills, 
2003).   
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encounter risks, including the malevolence and manipulation observed by Fry, and it 
is important to note that the US too have not yet established a workable model.  
 
Activists will therefore continue generating evidence to build the case for policy 
reform. Medical consumers are playing a key role as legalisation for medical use has 
been seen as a precursor to legalisation for recreational use (Kilmer and MacCoun, 
2017). 
 
They will also have to reconcile dramatically different approaches to realising the 
aspired cannabis economy. On the one hand there is the sharing, not for profit, 
model exemplified by the best examples of the CSCs, or the apomedication networks 
(Klein and Potter, 2018) of cannabis healers that are becoming alternative forms of 
healthcare provision. Bypassing markets and medical establishments these shifts 
towards autarchy and the sharing economy somehow reconnects cannabis with the 
counter cultural protests of the 1960s. Developing a sharing economy from the 
grassroots poses a challenge to traditional regulatory thought, where cannabis is 
controlled by the government, the free market and/or the medical establishment. 
Regulatory power is devolving to local, social movements here, which facilitates a 
greater level of individual control over the cannabis production and distribution 
process. This allows consumers to create and shape their own cannabis culture, 
reminiscent of the anti-authoritarian movements in the 1960s. 
 
On the other hand, the influx of capital from profit-oriented commercial corporations 
are piling into this potential market. Organisations such as Leafly are already 
developing sophisticated lobbying operations, using public relations to target policy 
makers and opinion formers. The objective is to open a market for a commodity, not 
to facilitate - home growing, healing and community – the ‘cannabis culture’ or ethos 
that is being promoted by the personal narratives of the activists and medical 
consumers in this special issue.  
 
It is likely that the community will remain divided in its attitude. And while the ‘small is 
beautiful’ ethos has a lot of merit for product innovation, authenticity and for allowing 
a cottage industry type of control there are clear limitations. Advances in the 
demonstrable efficacy of cannabis medication require the controlled conditions, 
including of the cannabis input, that at present only large scale pharmaceutical 
enterprises can provide. Furthermore, cannabis online markets abound with 
opportunists and downright fraudsters, preying on the desperation of patients or the 
confusion of operators in a poorly regulated environment. Similarly, some CSCs 
refuse to follow the not for profit model, and are operating as ‘shadow clubs’ 
(Decorte, 2015: 128), selling cannabis strains for extortionate amounts, exploiting 
both medical and non-medical consumers alike. 
 
Coming in from the cold 
 
Some of the organisations behind the parliamentary protest, like the United Patients 
Alliance who are now spearheading the medical reform movement in the UK, are 
open in their support for commercial players. Others are reluctant, and fear that 
legislative change, if it does come, will only facilitate corporate profit, without 
establishing the right to grow your own. For instance, the UKCSC (2016), who 
advocate for medical and non-medical use, have established a ‘Right2Grow’ 
campaign, which emphasises the right to grow, share and collectively consume 
cannabis.  
 
In any event, both these advocacy groups recognise the importance of telling human 
stories to allow change and they both followed Alfie’s story all the way to the protest 
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at Parliament on the 23rd of February 2018. Four of the articles in this special issue 
are authored by cannabis activists or medical consumers, with Godfrey, Bone and 
De Hoedt, and Fry going even further, offering a personal narrative of their own 
cannabis journeys. This special issue is therefore unique in the drug policy field, 
since it incorporates non-academic perspectives and narratives within an academic 
journal.  
 
Telling these human stories facilitates knowledge production by inputting cannabis 
consumer experiences into the evidence base. Policy scientists, communication 
scholars, psychologists and other social scientists are beginning to recognise the 
importance of telling good stories, to appeal to the emotions of policy makers and to 
the general public (Davidson, 2017). Although presenting the evidence is vital, 
finding reform champions and telling stories engages people on an emotive, human 
level, which speaks to their values (Rolles, 2016). 
 
This is especially important for those researchers questioning ‘evidence based policy’ 
(EBP) - what the concept of ‘evidence’ even means, and who gets to speak 
authoritatively  (see Lancaster et al, 2017a; 2017b; Ritter, Lancaster and Diprose, 
2018 on the ‘EBP’ paradigm in drug policy) - since important policy debates cannot 
be answered by simply turning to the evidence (Davidson, 2017). Policy decision 
making invariably involves questions of values – of how the world ‘ought to be’ as 
opposed to relying solely on the facts. Arguing from a position of moral authority 
alongside the evidence makes the reform position stronger. 
 
Alfie’s story could be a game changer. More than 370,000 people have signed a 
petition since hearing his plight, calling for the Home Office to grant a special licence 
to allow him to use medical cannabis (BBC, 2018). Appealing to policy makers’ and 
the publics’ morality and values could facilitate legal change. Whichever way the 
change comes for Alfie, (via the sharing economy or via corporations), as for many 
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